Abstract
Neurodegenerative diseases of the central nervous system (CNS) represent a large group of sporadic or inherited conditions which share the fundamental physiopathological feature of a progressive dysfunction and death of neurons belonging to different systems, which ultimately leads to regional and global brain atrophy. Although considerable advances in understanding the etiopathogenesis of these diseases have been made, to date no treatment capable of halting the progression of neurodegeneration in any of these diseases is available.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Mascalchi M, Filippi M, Floris R et al (2005) Diffusion-weighted MR of the brain: methodology and clinical applications. Radiol Med (Turin) 109:155–197
Ramani A, Jensen JH, Helpern JA (2006) Quantitative MR imaging in Alzheimer’s disease. Radiology 241:26–43
Gill SS, Small RK, Thomas DG et al (1989) Brain metabolites as 1HNMR markers of neuronal and glial disorders. NMR Biomed 2:196–200
Ashburner J, Csernansky JG, Davatzikos C et al (2003) Computer-assisted imaging to assess brain structure in healthy and diseased brain. Lancet Neurol 2:79–88
Bozzali M, Franceschi M, Falini A et al (2001) Quantification of tissue damage in AD using diffusion tensor and magnetization transfer MRI. Neurology 57:1135–1137
Mascalchi M, Lolli F, Della Nave R et al (2004) Volumetric, diffusion and magnetization transfer MR imaging of the brain in individuals with Huntington’s disease. Radiology 232:867–873
Falini A, Bozzali M, Magnani G et al (2005) A whole brain MR spectroscopy study from patients with Alzheimer’s disease and mild cognitive impairment. NeuroImage 26:1159–1163
Blennow K, de Leon M, Zetterberg H (2006) Alzheimer’s disease. Lancet Neurol 368:387–403
Jack CR, Shiung MM, Gunter JL et al (2004) Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62:591–600
Testa C, Laakso MP, Sabattoli F et al (2004) A comparison between the accuracy of voxel-based morphometry and hippocampal volumetry in Alzheimer’s disease. J Magn Reson Imaging 19:274–282
Baron JC, Chételat G, Desgranges B et al (2001) In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer’s disease. NeuroImage 14:298–309
Chételat G, Landeau B, Eustache F et al (2005) Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. NeuroImage 27:934–946
Frisoni G, Testa C, Sabattoli F et al (2005) Structural correlates of early and late onset Alzheimer’s disease: voxel based morphometry study. J Neurol Neurosurg Psychiat 76:112–114
Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, Rossor MN (1996) Presymptomatic hippocampal atrophy in Alzheimer’s disease: a longitudinal MRI study. Brain 119:2001–2007
Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen J, Rossor M (2001) Imaging of onset and progression of Alzheimer’s disease with voxel-compression mapping of serial magnetic resonance images. Lancet 358:201–205
Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, Fox NC (2006) Tracking atrophy progression in familial Alzheimer’s disease: a serial MRI study. Lancet Neurol 5:828–834
Kantarci K, Jack CR, Yu YC et al (2001) Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology 219:101–107
Sandson TA, Felician O, Edelman RR, Warach S (1999) Diffusion-weighted magnetic resonance imaging in Alzheimer’s disease. Dementia Geriatr Cogn Disord 10:166–171
Xie S, Xiao JX, Gong GL et al (2006) Voxel-based detection of white matter abnormalities in mild Alzheimer disease. Neurology 66:1845–1849
Umahara T, Tsuchiya K, Ikeda K et al (2002) Demonstration and distribution of taupositive glial coiled body-like structures in white matter and white matter threads in early onset Alzheimer’s disease. Neuropathology 22:9–12
Hanyu H, Asano T, Iwamoto T et al (2000) Magnetization transfer measurements of the hippocampus in patients with Alzheimer’s disease, vascular dementia, and other types of dementia. AJNR Am J Neuroradiol 21:1235–1242
Valenzuela MJ, Sachdev P (2001) Magnetic resonance spectroscopy in AD. Neurology 56:592–598
Block W, Jessen F, Traber F et al (2002) Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease. Arch Neurol 59:828–834
Godbolt AK, Waldman AD, MacManus DG et al (2006) MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 66:718–722
Jessen F, Traeber F, Freymann K et al (2006) Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 67:528–530
Backman L, Andersson JL, Nyberg L et al (1999) Brain regions associated with episodic retrieval in normal aging and Alzheimer’s disease. Neurology 52:1861–1870
Rémy F, Mirrashed F, Campbell B, Richter W (2005) Verbal episodic memory impairment in Alzheimer’s disease: a combined structural and functional MRI study. NeuroImage 25:253–266
Aylward EH, Brandt J, Codori AM et al (1994) Reduced basal ganglia volume associated with the gene for Huntington’s disease in asymptomatic at-risk persons. Neurology 44:823–828
Rosas HD, Goodman J, Chen YI et al (2001) Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 57:1025–1028
Aylward EH, Codori AM, Rosenblatt A et al (2000) Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease. Mov Disord 15:552–560
Kassubek J, Juengling FD, Kioschies T et al (2004) Topography of cerebral atrophy in early Huntington’s disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiat 75:213–220
Gavazzi C, Della Nave R, Petralli R et al (2007) Combining functional and structural MR imaging of the brain in Huntington disease. J Comput Assist Tomogr (in press)
Thieben MJ, Duggins AJ, Good CD et al (2002) The distribution of structural neuropathology in pre-clinical Huntington’s disease. Brain 125:1815–1828
Seppi K, Schocke MF, Mair KJ et al (2006) Diffusion-weighted imaging in Huntington’s disease. Mov Disord 21(7):1043–1047
Jenkins B, Koroshetz W, Beal MF, Rosen B (1993) Evidence for an energy metabolism defect in Huntington’s disease using localized proton spectroscopy. Neurology 43:2689–2695.
Harms L, Meierkord H, Timm G et al (1997) Decreased N-acetylaspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington’s disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiat 62:27–30
Jenkins BG, Rosas HD, Chen CI et al (1998) 1HNMR spectroscopy studies of Huntington’s disease: correlations with CAG repeat numbers. Neurology 50:1357–1365
Tabrizi SJ, Blamire AM, Manners DN et al (2003) Creatine therapy for Huntington’s disease: clinical and MRS findings in a 1-year pilot study. Neurology 61:141–142
Reading SAJ, Dziorny AC, Peroutka LA et al (2004) Functional brain changes in presymptomatic Huntington’s disease. Ann Neurol 55:879–883
Paulsen JS, Zimbelman JL, Hinton SC et al (2004) fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington’s disease. AJNR Am J Neuroradiol 25:1715–1721
Burton EJ, McKeith IG, Burn DJ et al (2004) Cerebral atrophy in Parkinson’s disease with and without dementia: a comparison with Alzheimer’s disease, dementia with Lewy bodies and controls. Brain 127:791–800
RamÃrez-Ruiz B, Martà MJ, Tolosa E et al (2005) Longitudinal evaluation of cerebral morphological changes in Parkinson’s disease with and without dementia. J Neurol 252:1345–1352
Nagano-Saito A, Washimi Y, Arahata Y et al (2005) Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 64:224–229
Summerfield C, Junqué C, Tolosa E et al (2005) Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 62:281–285
Price S, Paviour D, Scahill R et al (2004) Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson’s disease. NeuroImage 23:663–669
Hanyu H, Asano T, Sakurai H et al (2001) Magnetisation transfer measurements of the subcortical grey and white matter in Parkinson’s disease with and without dementia and in progressive supranuclear palsy. Neuroradiology 43:542–546
Tambasco N, Pelliccioli GP, Chiarini P et al (2003) Magnetization transfer changes of gray and white matter in Parkinson’s disease. Neuroradiology 45:224–230
Eckert T, Sailer M, Kaufmann J et al (2004) Differentiation of idiopathic Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy and healthy controls using magnetization transfer imaging. NeuroImage 21:229–235
Seppi K, Schocke MF, Esterhammer R et al (2003) Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the Parkinson variant of multiple system atrophy. Neurology 60:922–927
Schocke MF, Seppi K, Esterhammer R et al (2004) Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson’s disease. NeuroImage 21:1443–1451
Yoshikawa K, Nakata Y, Yamada K, Nakagawa M (2004) Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J Neurol Neurosurg Psychiat 75:481–484
Scherfler C, Schocke MF, Seppi K et al (2006) Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson’s disease. Brain 129:538–542
Bowen BC, Block RE, Sanchez-Ramos J et al (1995) Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am J Neuroradiol 16:61–68
Hu MT, Taylor-Robinson SD, Chaudhuri KR et al (2000) Cortical dysfunction in non-demented Parkinson’s disease patients: a combined 31P-MRS and 18FDG-PET study. Brain 123:340–352
Haslinger B, Erhard P, Kampfe N et al (2001) Event-related functional magnetic resonance imaging in Parkinson’s disease before and after levodopa. Brain 124:558–570
Klockgether T, Skalej M, Wedekind D et al (1998) Autosomal dominant cerebellar ataxia type I: MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain 121:1678–1693
Guerrini L, Lolli F, Ginestroni A et al (2004) Brainstem neurodegeneration correlates with clinical dysfunction in SCA1 but not in SCA2: a volumetric, diffusion and quantitative proton spectroscopy MR study. Brain 127:1785–1795
Brenneis C, Bosch SM, Schocke M et al (2003) Atrophy pattern in SCA2 determined by voxel-based morphometry. Neuroreport 14:1799–1802
Mascalchi M, Tosetti M, Plasmati R et al (1998) Proton magnetic resonance spectroscopy in an Italian family with spinocerebellar ataxia type 1. Ann Neurol 43:244–252
Boesch SM, Schoecke M, Burk K et al (2001) Proton magnetic resonance spectroscopic imaging reveals differences in spinocerebellar ataxia types 2 and 6. J Magn Reson Imaging 13:553–539
Viau M, Machand L, Bard C, Boulanger Y (2005) 1H magnetic resonance spectroscopy of autosomal ataxias. Brain Res 1049:191–202
Richter S, Dimitrova A, Maschke M et al (2005) Degree of cerebellar ataxia correlates with three-dimensional MRI-based cerebellar volume in pure cerebellar degeneration. Eur Neurol 54:23–27
Della Nave R, Foresti S, Tessa C et al (2004) ADC mapping of neurodegeneration in the brainstem and cerebellum in patients with progressive ataxias. NeuroImage 22:698–705
Mascalchi M, Cosottini M, Lolli F et al (2002) Proton MR spectroscopy of the cerebellum and pons in patients with degenerative ataxia. Radiology 223:371–378
Terakawa H, Abe K, Watanabe Y et al (1999) Proton magnetic resonance spectroscopy (1H MRS) in patients with sporadic cerebellar degeneration. J Neuroimaging 9:72–77
Ellis CM, Suckling J, Amaro E Jr, et al (2001) Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS. Neurology 57:1571–1578
Valsasina P, Agosta F, Benedetti B et al (2006) Diffusion anisotropy of the cervical cord is strictly associated with disability in ALS. J Neurol Neurosurg Psychiat [epub 9 Oct 2006; doi:10.1136/jnnp.2006.100032]
Ellis CM, Simmons A, Jones DK et al (1999) Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology 53:1051–1058
Sach M, Winkler G, Glauche V et al (2004) Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain 127:340–350
Ulug AM, Grunewald T, Lin MT et al (2004) Diffusion tensor imaging in the diagnosis of primary lateral sclerosis. J Magn Reson Imaging 19:34–39
Tanabe JL, Vermathen M, Miller R et al (1998) Reduced MTR in the corticospinal tract and normal T2 in amyotrophic lateral sclerosis. Magn Reson Imaging 16:1163–1169
Chan S, Shungu DC, Akinwande D et al (1999) Motor neuron diseases: comparison of single voxel-proton MR spectroscopy of the motor cortex with MR imaging of the brain. Radiology 212:763–769
Kalra S, Cashman NR, Genge A, Arnold DL (1998) Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 9:1757–1761
Konrad C, Henningsen H, Bremer J et al (2002) Pattern of cortical reorganization in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Exp Brain Res 143:51–56
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Italia
About this chapter
Cite this chapter
Mascalchi, M. (2007). Other Neurodegenerative Conditions. In: Filippi, M., Rovaris, M., Comi, G. (eds) Neurodegeneration in Multiple Sclerosis. Topics in Neuroscience. Springer, Milano. https://doi.org/10.1007/978-88-470-0391-0_14
Download citation
DOI: https://doi.org/10.1007/978-88-470-0391-0_14
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0390-3
Online ISBN: 978-88-470-0391-0
eBook Packages: MedicineMedicine (R0)